Major finding: The rate of relapse was 27% in patients whose cumulative dose of isotretinoin exceeded 220 mg/kg and 47% in patients with a cumulative dose below 220 mg/kg (P = .029).
Data source: A prospective, observational intervention study of 116 patients with treatment-resistant nodulocystic acne.
Disclosures: Dr. Stamey reported having no relevant financial disclosures.
MILWAUKEE– Boosting cumulative isotretinoin doses above 220 mg/kg significantly reduced the risk of relapse without dramatically increasing side effects in patients with severe, treatment-resistant nodulocystic acne in a prospective, observational study.
During the 12-month study, 27% of patients who received more than 220 mg/kg and 47% of those who received less than 220 mg/kg had a relapse, defined as treatment with another prescription acne medicine (P = .029).
The number of patients needing retreatment with isotretinoin was similar in both groups (2 vs. 0; P = .31), Mr. Christopher Stamey reported at the annual meeting of the Society for Pediatric Dermatology.Full Article